Jazz Pharmaceuticals (NASDAQ:JAZZ) Price Target Raised to $202.00 at JPMorgan Chase & Co.

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price target lifted by analysts at JPMorgan Chase & Co. from $190.00 to $202.00 in a research note issued on Monday, Benzinga reports. The firm currently has an “overweight” rating on the specialty pharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 75.70% from the company’s previous close.

Other analysts have also issued reports about the company. Needham & Company LLC lowered their target price on Jazz Pharmaceuticals from $208.00 to $205.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Morgan Stanley dropped their price objective on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating on the stock in a report on Friday, July 12th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 1st. Robert W. Baird lowered their price target on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating on the stock in a research report on Thursday, August 1st. Finally, Barclays cut their price objective on shares of Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Friday, May 3rd. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $173.07.

Jazz Pharmaceuticals Stock Up 0.6 %

Jazz Pharmaceuticals stock opened at $114.97 on Monday. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $146.70. The company has a quick ratio of 1.90, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The firm has a 50 day moving average price of $108.98 and a 200-day moving average price of $113.18. The company has a market capitalization of $7.25 billion, a P/E ratio of 23.71, a P/E/G ratio of 1.76 and a beta of 0.58.

Institutional Trading of Jazz Pharmaceuticals

A number of large investors have recently modified their holdings of the business. International Assets Investment Management LLC purchased a new stake in Jazz Pharmaceuticals in the fourth quarter valued at approximately $7,201,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Jazz Pharmaceuticals by 29.1% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 39,113 shares of the specialty pharmaceutical company’s stock worth $4,811,000 after acquiring an additional 8,814 shares during the last quarter. Daiwa Securities Group Inc. grew its position in Jazz Pharmaceuticals by 15.5% in the fourth quarter. Daiwa Securities Group Inc. now owns 4,707 shares of the specialty pharmaceutical company’s stock worth $579,000 after acquiring an additional 631 shares in the last quarter. abrdn plc increased its stake in Jazz Pharmaceuticals by 442.2% in the fourth quarter. abrdn plc now owns 56,230 shares of the specialty pharmaceutical company’s stock valued at $6,916,000 after acquiring an additional 45,860 shares during the last quarter. Finally, Duality Advisers LP raised its position in Jazz Pharmaceuticals by 35.8% during the fourth quarter. Duality Advisers LP now owns 25,641 shares of the specialty pharmaceutical company’s stock valued at $3,154,000 after purchasing an additional 6,758 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.